Markets

Dual-class shares are a sugar-hit solution that risk diluting investor rights and diverting attention from genuine market reform.

Potential buyers are eyeing Mayne Pharma’s Adelaide factory at the centre of its takeover saga, giving investors hope the deal could still be salvaged.

The financial services giant has revealed it is preparing internal candidates to succeed Shemara Wikramanayake when she eventually exits.